Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic • Annals of Oncology Journal Club
How do you modify your adjuvant therapy course in a patient experiencing liver dysfunction within the first few months of starting CDK4/6i?
For a patient recently started on therapy who develops severe transaminitis (AST and ALT >10–15× ULN) which does not readily improve in first few weeks after drug discontinuation, would you still try to incorporate the same or alternate CDK 4/6i after eventual resolution? Or continue endocrine therapy alone?
Answer from: Medical Oncologist at Community Practice
We will adhere to the CTCAE grading system. Most of these patients do well with dose reduction and interruption. If persistent grade 2/3, will likely change to an alternate CDK agent and evaluate whether it solves LFT issues.
Sign In or Register to read more